Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma

Mark Warren, MBBS, FRACP1,2; Michael Kolinsky, MD, FRCP1,3; Christina M. Canil, MD, FRCP4,5; Piotr Czaykowski, MD, MSc, FRCP6,7; Srikala S. Sridhar, MD, FRCP8; Peter C. Black, MD, FRCS, FACS9; Christopher M. Booth, MD, FRCP10; Wassim Kassouf, MD, CM, FRCS11; Libni Eapen, MD, FRCP5,12; Som D. Mukherjee, MD, MSc, FRCP13; Normand Blais, MD, MSc, FRCP14; Bernhard J. Eigl, MD, FRCP15; Eric Winquist, MD, MSc16; Naveen S. Basappa, MD, FRCP1,3; Scott A. North, MD, FRCP1,3; on behalf of GUMOC

1Department of Medical Oncology, Cross Cancer Institute, Edmonton, AB, Canada; 2Cancer Centre, Bendigo Health, Bendigo, Australia; 3University of Alberta, Edmonton, AB, Canada; 4The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; 5Ottawa Hospital Research Institute, Ottawa, ON, Canada; 6Cancer Care Manitoba, Winnipeg, MB, Canada; 7University of Manitoba, Winnipeg, MB, Canada; 8Division of Hematology and Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada; 9Department of Urological Sciences, University of British Columbia, Vancouver, BC, Canada; 10Department of Oncology, Queen’s University, Kingston, ON, Canada; 11Department of Surgery, McGill University Health Centre, Montreal, QC, Canada; 12Division of Radiation Oncology, University of Ottawa, ON, Canada; 13Juravinski Cancer Centre, Hamilton, ON, Canada; 14Division of Medical Oncology/Hematology, Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada; 15BC Cancer, Vancouver, BC, Canada; 16Division of Medical Oncology, Western University and London Health Sciences Centre, London, ON, Canada

Cite as: Can Urol Assoc J 2019 April 26; Epub ahead of print. http://dx.doi.org/10.5489/cuaj.6015

Published online April 26, 2019

***

Introduction

In Canada, bladder cancer ranks as the 5th most common cancer with an estimated 8900 new cases and 2400 deaths in 2018.1 Approximately 15% of patients have locally advanced or metastatic disease at presentation. A further 40 – 50% of those with muscle invasive early stage disease will relapse after initial treatment. The majority of patients with advanced stage disease will succumb to their disease. Cancers of the ureter, renal pelvis and proximal urethra constitute approximately 5-10% of cases of urothelial carcinoma and are treated with similar systemic therapy as bladder cancer.

GUMOC (Genitourinary Medical Oncologists of Canada) is comprised of Canadian Medical Oncologists who specialize in the treatment of genitourinary cancers. With recent
advances in systemic therapy, especially due to the emergence of immunotherapy as a therapeutic option, a consensus opinion has become necessary to guide the management of unresectable locally advanced and metastatic urothelial carcinoma.

Methods
A literature review was undertaken evaluating studies of unresectable locally advanced and metastatic urothelial carcinoma with a greater emphasis on prospective randomized studies. A search of Medline, Embase and Pubmed in addition to other published guidelines was used to identify relevant studies. A summary of the evidence was created with draft recommendations pertaining to various aspects of the management of advanced urothelial carcinoma. This was distributed to members of GUMOC for review and discussion through which a consensus opinion was established.

The following statements focus predominantly on systemic management which falls in the realm of the Medical Oncology specialty. Additionally, the management of advanced, unresectable urothelial cancer is multidisciplinary in nature as there are times when surgery and / or radiotherapy have a role to play, particularly in patients with oligometastatic disease and those with locally advanced disease. In this consensus statement, we define locally advanced disease as cT4b and / or cN1-3. Statements pertaining to these aspects of management are intended to provide guidance for treating clinicians as to when to consider referral for multidisciplinary discussion. They are not intended to mandate a particular management plan that arises from such a forum. All recommended systemic treatment regimens are outlined in Table 1.

Systemic therapy for unresectable locally advanced and metastatic urothelial carcinoma

Eligibility for cisplatin-based chemotherapy

- Routine eligibility for cisplatin chemotherapy includes all of: (1) creatinine clearance ≥ 60ml/min, (2) ECOG performance status of ≤ 1, (3) absence of hearing loss ≥ Gr 2 (CTCAE), (4) absence of neuropathy ≥ Gr 2 (CTCAE), and (5) absence of NYHA grade III / IV heart failure.
- In select cases, eligibility criteria may be extended to patients with GFR of 45 - 60mls/min and / or ECOG 2 performance status. Administering split dose cisplatin is an option for these patients.

A consensus definition of eligibility for cisplatin chemotherapy was developed by members of a working party, who combined the results of a survey of 120 medical oncologists involved in research of urothelial carcinoma with an evaluation of the available literature on this topic. The purpose was to develop a consistent definition for clinical trial eligibility. The criteria generated were good performance status (ECOG 0 -1); GFR > 60mls / min, and absence of contra-indications to cisplatin such as grade ≥ 2 neuropathy, grade ≥ 2 hearing loss and NYHA grade III/IV heart failure. Several studies have used split dose cisplatin to patients with a GFR
as low as 35 – 40mls / min and reported acceptable safety outcomes.\textsuperscript{3,4} In practice, cisplatin is rarely used in patients with a GFR < 45mls/min.

**First-line systemic therapy**

1. **Patient eligible for cisplatin-based chemotherapy:**
   - In patients suitable for cisplatin based chemotherapy, the preferred routine regimen is gemcitabine / cisplatin (GC).
   - Dose dense methotrexate, vinblastine, doxorubicin and cyclophosphamide (DD-MVAC) with growth factor support may be considered in select cases where a more aggressive treatment approach is being considered.

Gemcitabine/cisplatin was compared to the earlier standard of methotrexate, vinblastine, doxorubicin and cyclophosphamide (MVAC) in a phase III randomized trial. GC demonstrated similar efficacy but with reduced toxicity. In an updated analysis with a minimum of 5 years of follow up, median overall survival (OS) was 14 months in the GC arm, with a 13% 5 year survival rate, which was not significantly different from the MVAC arm. The hazard ratio of GC compared to MVAC was 1.09 (95% CI 0.88 – 1.34; \( P=0.66 \)).\textsuperscript{5} Toxicity was increased in the MVAC arm with a higher rate of grade 3-4 neutropenic sepsis (12% vs 1%), mucositis (22% vs 1%) and toxic death (3% vs 1%).\textsuperscript{6}

The small proportion of long-term survivors is seen predominantly in patients with good performance status (ECOG 0 – 1, KFS > 80) and in those patients without visceral metastases (bone, lung, liver).\textsuperscript{5,7} Further attempts have been made to improve on these results by intensifying doses and adding additional chemotherapy agents. One notable regimen is DD-MVAC tested in the phase III EORTC 30924 study. This regimen consists of two weekly MVAC with growth factor support and was compared to standard MVAC. Seven year follow up demonstrated a statistically borderline improvement in overall survival with a 5 year OS of 21.8% in DD-MVAC treated patients compared to 13.5% with standard MVAC. The hazard ratio of DD-MVAC compared to standard MVAC was 0.76 (95% CI 0.58 – 0.99, \( P=0.042 \)). A compete response (CR) was seen in 21% of those receiving DD-MVAC compared with 9% of those receiving standard dose MVAC. The addition of growth factor support reduced neutropenic complications and mucositis in the DD-MVAC arm compared with the standard MVAC arm, however there was still one death due to toxicity in each treatment arm.\textsuperscript{8}

Evidence for other regimens is not sufficiently robust to endorse their inclusion as recommended treatments. Dose dense GC (DD-GC) was compared to the DD-MVAC regimen in a phase III study performed by the Hellenic Oncology group. Although DD-GC demonstrated similar efficacy to DD-MVAC with reduced toxicity, the study was underpowered with imbalances in the treatment arms.\textsuperscript{9} Concerns regarding vascular toxicity with this regimen were raised as a result of a neoadjuvant study of DD-GC for muscle invasive bladder cancer in which 23% of patients experienced grade 3-4 venous and arterial events.\textsuperscript{10} The addition of paclitaxel to GC (PGC) was tested in the phase III EORTC Intergroup 30987 study consisting of 626 patients.
There was a non-significant 3.2 month median OS improvement favoring PGC in the intention-to-treat (ITT) patient population which reached statistical significance when 47 patients not meeting the eligibility criteria were excluded. An unplanned subgroup analysis revealed benefit in the 81% of patients with bladder primary. Febrile neutropenia was increased in the PGC arm at 13.2% compared to 4.3%.\textsuperscript{11}

Currently, there are no completed clinical trials supporting the use of first line immunotherapy in cisplatin eligible patients. However, numerous trials are currently evaluating the role of first line immunotherapy (table 5).

2. Patient ineligible for cisplatin-based chemotherapy

- In patients ineligible for cisplatin-based chemotherapy, the preferred regimen is gemcitabine / carboplatin (GCa)
- In patients not suitable for combination chemotherapy, single agent gemcitabine, paclitaxel or docetaxel is recommended.
- Immunotherapy is not routinely recommended in the first line setting for cisplatin-ineligible patients.

Chemotherapy in cisplatin-ineligible patients

Carboplatin based regimens are inferior to cisplatin-based regimens with lower response rates and trend towards inferior survival.\textsuperscript{12} Nonetheless, carboplatin is active in urothelial carcinoma and is the cornerstone of preferred regimens in cisplatin-ineligible patients. Gemcitabine / carboplatin (GCa) was compared to M-CAVI (methotrexate, carboplatin, vinblastine) in the phase III EORTC 30986 study. The population studied was ineligible for cisplatin on the basis of a GFR of 30 – 60mls/min (55% of patients), WHO PS of 2 (17.6%) or both (27.3%). Visceral metastases were present in 51% of patients. Efficacy was similar in both regimens with a median OS of 9.3 months for GCa and 8.1 months with M-CAVI. Only 8% of patients were still alive after a median follow up of 4.5 years. Toxicity was reduced with GCa compared to M-CAVI with 9% cases of severe acute toxicity (SAT) and 2 toxic deaths compared to 21% cases of SAT and 4 toxic deaths, respectively.\textsuperscript{13} Gemcitabine / carboplatin has thus become the preferred regimen in this generally less robust group of patients.

Several other carboplatin and non-carboplatin based regimens have been evaluated in phase II studies. Although demonstrating encouraging results, none of these regimens has been further assessed in phase III studies and are not considered standard regimens.\textsuperscript{14–21} Paclitaxel and gemcitabine has demonstrated overall response rates of between 37 – 70%, however pulmonary toxicity has been noted.\textsuperscript{19}

In patients not suitable for combination therapy, single agent gemcitabine, paclitaxel or docetaxel has been studied in small single arm phase II studies.\textsuperscript{22–25} Response rates have varied between 25 – 47% but have generally been of short duration with median OS ranging between 8 – 12 months in these series.
Unresectable locally advanced and metastatic urothelial carcinoma

Immunotherapy in cisplatin-ineligible patients

Checkpoint inhibitors active on the PD-1 / PD-L1 interaction between tumour cells and cytotoxic T cells, have demonstrated efficacy in a first line setting in cisplatin-ineligible patients with advanced UC. Pembrolizumab, a monoclonal antibody against the PD-1 receptor on T cells and other immune cells, was evaluated in 370 cisplatin-ineligible patients with advanced urothelial carcinoma in a single arm phase II study. An ORR of 29% was in the range of that seen with chemotherapy, with a potential advantage over chemotherapy existing in both the durability of responses and overall tolerability of this regimen. Sixty eight percent of responses were ongoing at 12 months and grade 3-4 toxicity mostly from immune-related adverse events (irAEs) was seen in 16% (Table 2). Median OS was 11.5 months. Responses were more likely in patients with PD-L1 positivity on immunohistochemistry (IHC) as measured by a combined positive score (CPS) ≥ 10%. Similar outcomes were obtained with atezolizumab which is a monoclonal antibody against the PD-L1 receptor on tumour and immune cells. In a single arm, phase II study in 119 patients, the ORR was 23% with 70% of responses ongoing after a median follow up of 17.2 months and a median OS of 15.9 months. Grade 3 / 4 toxicity was seen in 16% of patients. The differential effect of PD-L1 expression by IHC on ORR% was not as obvious (Table 2).

GUMOC currently does not endorse these agents for first line therapy. This is discussed below in ‘Current approvals and status of the evidence of immunotherapy in advanced UC’.

Second-line systemic therapy:

1. In patients who have progressive disease during or after platinum-based chemotherapy, pembrolizumab is the preferred regimen (if available)
2. Where pembrolizumab is unavailable or a patient is ineligible, single agent paclitaxel or docetaxel is preferred for the majority of patients.
3. Re-treatment with a platinum based regimen is a reasonable option in a patient who has disease progression following a prolonged (> 6 – 12 month) initial response to platinum-based chemotherapy.

Chemotherapy

Prior to the advent of checkpoint inhibitors in unresectable locally advanced and metastatic UC, there was no standout salvage chemotherapy regimen for patients progressing during or after platinum-based regimens. Re-treatment with a platinum regimen can be a successful strategy in patients with an initial response lasting greater than 6 – 12 months.  Patients progressing within this timeframe are likely to be refractory to further platinum therapy. The only randomized phase III study in this group of patients compared vinflunine to best supportive care. Although OS was not improved in the ITT population, analysis of those patients fulfilling eligibility criteria revealed a median OS benefit of 2 months. Vinflunine is not available in North America. Although doublet chemotherapy regimens are associated with higher response
rates, their greater toxicity combined with failure to impact meaningfully on OS has limited their use.\textsuperscript{33} Despite low response rates of approximately 10\%, paclitaxel and docetaxel are well tolerated and have emerged as preferred regimens.\textsuperscript{34–36} NAB-paclitaxel has demonstrated efficacy in the second line setting and is a reasonable alternative.\textsuperscript{37}

2. Immunotherapy: Checkpoint inhibitors

The evidence supporting the use of checkpoint inhibitors in the second line setting is more robust than in the first line setting. Five checkpoint inhibitors have been tested in this setting including 2 in randomized phase III studies.

Pembrolizumab was compared to investigators’ choice of single agent paclitaxel, docetaxel or vinflunine in 542 patients with progressive disease during or after platinum based chemotherapy in the randomized phase III Keynote 045 study. Overall response rate was 21\% in the pembrolizumab-treated patients compared with 11\% in chemotherapy-treated patients. Median PFS was only 2.1 months on pembrolizumab compared with 3.3 months on chemotherapy (HR 0.98, 95\% CI 0.81 - 1.19, \(P=0.42\)) reflecting the small number of patients who responded to pembrolizumab. Nonetheless, responses were durable with 68\% ongoing at 12 months compared with only 35\% of chemotherapy responses ongoing at 12 months. Median OS was 10.3 months with pembrolizumab compared to 7.4 months on chemotherapy (HR 0.73, 95\% CI 0.59 – 0.91, \(p=0.002\)). Grade 3 – 5 toxicity was seen in 15\% of patients on pembrolizumab compared to 49\% on chemotherapy. Benefit was seen irrespective of the choice of chemotherapy given and irrespective of PD-L1 expression by CPS\%.\textsuperscript{38}

Atezolizumab was compared with investigators’ choice of paclitaxel, docetaxel or vinflunine in the phase III IMvigor 211 study, sharing a similar overall design with the Keynote 045 study. One important study design difference was the use of a hierarchical fixed-sequence procedure for endpoint analysis, according to PD-L1 expression. The primary endpoint of OS was tested in successive subgroups defined by PD-L1 expression: IC2/3 (\(\geq\) 5\% expression on tumour-infiltrating immune cells) followed by IC 1/2/3 (\(\geq\) 1\% expression on tumour-infiltrating immune cells) followed by the overall ITT group. Demonstration of superior OS was required in each group before the next group could be tested. No OS benefit was seen for atezolizumab compared with chemotherapy in the first group of 234 patients with IC2/3 positive disease. In this population, median OS was 11.1 months vs 10.6 months on chemotherapy (HR 0.87, \(p=0.41\)). A survival benefit favoring atezolizumab was seen in the exploratory analysis of the ITT population of 931 patients (HR 0.85, 95\% CI 0.73 – 0.99). In this study, PD-L1 positivity seemed to predict benefit from chemotherapy as well as immunotherapy. The theme of durable immunotherapy responses was seen in this study with median duration of response of 21.7 months in the ITT population compared with 7.4 months for chemotherapy in the ITT population.\textsuperscript{39}

Several single arm phase I and II studies have evaluated outcomes of checkpoint inhibitors in the second line setting as outlined in Table 3.\textsuperscript{40–47} Response rates have ranged
between 15 – 31% with complete responses ranging between 2% and 11%. Median progression free survival has ranged between 1.6 months and 2.8 months, reflecting the relatively overall low proportion who benefit. Nonetheless, those who do respond seem to obtain durable benefit. Grade 3 – 5 toxicity has been observed in 8 – 22% of patients.

**The role of PD-L1 testing in selecting patients for immunotherapy**

- In the second line setting PD-L1 testing by IHC should not be used to select patients for immunotherapy

  In the second line setting, findings from both the Keynote 045 and IMvigor 211 randomized phase III studies suggest that benefit of checkpoint inhibitors is not limited to those with PD-L1-positive tumours by IHC. In Keynote 045, the ORR to pembrolizumab was similar in the CPS ≥ 10% population (22%) compared to the overall population (21%). Superior OS of pembrolizumab compared with chemotherapy was demonstrated in both the CPS ≥10% population and the overall population. In the IMvigor 211 trial, ORR was higher in the IC2/3 population (23%) compared to the ITT population (13%). Paradoxically, superior OS of Atezolizumab compared with chemotherapy was seen in the exploratory analysis of the ITT population, but not in the primary analysis of the IC2/3 subgroup.

  Di Nunno et al combined the results of both randomized control trials (RCTs) in a meta-analysis and found that immunotherapy improved OS in the ITT population but not in the high PD-L1 population. Heterogeneity between trials was greater in the PD-L1 high population compared with the ITT population demonstrating the need to further elucidate the role of PD-L1 as a predictive biomarker.

  As illustrated in Tables 1 and 2, numerous phase I and II studies of checkpoint inhibitors have evaluated ORR according to PD-L1 status in both first and second line settings. In some, but not all studies, PD-L1 positivity has been associated with a higher ORR. These findings are exploratory in nature. To date no single biomarker has been able to predict response to I-O therapies in urothelial carcinoma.

  In the first line setting, the role of PD-L1 as a predictive biomarker will become clearer once results from ongoing RCTs become available. Recent safety reports have been issued from the Data Monitoring Committees of two current phase III trials comparing PD-1 / PD-L1 inhibitors (pembrolizumab in Keynote – 361, and atezolizumab in IMvigor 130) to either cisplatin or carboplatin combined with gemcitabine in first line urothelial carcinoma. Reduced efficacy of checkpoint blockade compared to chemotherapy was observed in patients with low PD-L1 expression.

**Current approvals and the status of the evidence of immunotherapy in advanced urothelial carcinoma**

In the first line setting, neither pembrolizumab nor atezolizumab has been approved by Health Canada (Health Canada, 2018). Both agents received accelerated approval by both the FDA
(Food and Drug Administration) and the EMA (European Medicines Agency) for cisplatin-ineligible patients,\textsuperscript{50,52} and are endorsed by NCCN in this population.\textsuperscript{53} Recently the indication has been narrowed to those patients whose tumours are PD-L1 positive, or who are not eligible for any platinum chemotherapy regardless of PD-L1 expression. An application for first line pembrolizumab along similar lines to FDA and EMA approvals has been made to the Pan-Canadian Oncology Drug Review (pCODR).\textsuperscript{54}

In the second line setting, pembrolizumab, atezolizumab, durvalumab and avelumab have been approved by Health Canada for use in patients progressing during or following platinum-based chemotherapy or those who relapse within 12 months of receiving neoadjuvant or adjuvant platinum based chemotherapy for earlier stage disease.\textsuperscript{50} An expert review committee on behalf of pCODR recommended approval of pembrolizumab in this setting conditional upon ‘cost effectiveness being improved to an acceptable level’.\textsuperscript{54} All five PD-1 / PD-L1 inhibitors discussed have FDA approval in this setting and pembrolizumab, atezolizumab and nivolumab have EMA approval.\textsuperscript{50,52}

There was robust debate about the level of evidence required to recommend these agents particularly in first line setting for patients not suitable for platinum based chemotherapy. Nonetheless, the majority of GUMOC members preferred to maintain the standard of endorsing new treatments on the basis of both statistically significant and clinically meaningful benefit demonstrated in randomized phase III trials. Currently this level of evidence has not been achieved for pembrolizumab or atezolizumab in the first line setting. By the same standard, pembrolizumab is the only checkpoint inhibitor to have demonstrated this level of evidence in the second line setting. GUMOC recognize that the current consensus statements may need updating depending on the results of several ongoing phase III trials of checkpoint inhibitors (table 5).

Management of cT4b and / or cN1-3 urothelial carcinoma of the bladder:

\begin{itemize}
  \item Patients with clinically staged T4b or N1-3 urothelial carcinoma of the bladder should be discussed in a multidisciplinary forum including an experienced Urologist / Uro-Oncologist and Radiation Oncologist.
  \item Patients with cT4b and / or cN1-3 urothelial carcinoma of the bladder can be cured using multi-modality treatment.
  \item In suitable patients, the preferred approach is to commence systemic chemotherapy with 4 – 6 cycles of platinum based chemotherapy as per ‘first line systemic therapy’.
  \item Depending on response to initial chemotherapy, consolidation with either RC + pelvic lymph node dissection (PLND) or radical radiotherapy (+/- concurrent chemotherapy) can be administered.
\end{itemize}
In UC of the bladder, clinical T4b disease is defined as a tumour which invades the pelvic wall, abdominal wall or adjacent bowel / rectum and is unresectable unless significant downstaging can be achieved. Clinical N1-2 disease consists of lymph node involvement in the true pelvis, whereas N3 consists of common iliac lymph node involvement. Not all patients with regional node involvement will have distant metastases, particularly with cN1-2 stage disease. The definition of nodal metastases changed in 2010 with the 7th edition of the AJCC. In prior editions, common iliac lymph node involvement was considered to be metastatic and N1-3 defined nodes of varying number and size in the true pelvis.

Evidence defining the optimum treatment of cT4b and cN1-3 disease is limited to retrospective series. These patients have been routinely excluded from neoadjuvant chemotherapy trials, and in the Advanced Bladder Cancer meta-analysis of neo-adjuvant chemotherapy, represented only 1% and 4% of cases, respectively. Likewise, these patients have generally been excluded from chemoradiotherapy studies. Consequently the optimum management of this subgroup of patients is not well defined.

A commonly used treatment paradigm in published series has consisted of induction chemotherapy (IC) followed by RC or HDRT in select patients. Several studies utilizing this approach are outlined in Table 3. Only the study by Nieuwenhuijzen required histological confirmation of involved lymph nodes. Radical cystectomy / PLND was the most commonly used consolidation treatment with HDRT only utilized in a subset of patients in two studies. The study by Urakami included 29 patients with upper tract UC out of 60 patients. All other studies were restricted to UC of the bladder. Most studies did not define specific selection criteria for RC or HDRT, however the study by Nieuwenhuijzen required a response to induction chemotherapy in order to proceed to RC and the study by Urakami selected patients with responsive or stable disease. The study by Als had a unique design whereby patients who obtained a CR based on both CT imaging and cystoscopy and biopsy underwent close surveillance whereas patients who had a partial response received either RC or HDRT. Although the study by Herr did not define criteria for RC, 80 patients out of an initial 207 pts receiving chemotherapy proceeded to RC, implying that patients were carefully selected for surgery. The study by Black evaluated cT4b patients who had achieved sufficient downstaging from IC to become resectable. Most studies administered 4 cycles of chemotherapy. Results from the above studies demonstrate the potential for cure with reported 5 year cancer specific survival (CSS) / OS ranging from 23 – 60%. On this basis, GUMOC considered it reasonable to endorse the above treatment strategy for this group of patients. A further argument for a curative treatment approach is the potential for inaccurate clinical staging of lymph nodes. In studies of patients with cN1-3 who have proceeded directly to surgery a proportion have had pN0 disease implying false positive clinical staging. A benefit of commencing treatment with IC is to spare patients who have significant disease progression the morbidity of surgery and / or HDRT.
Selection criteria which should be applied to the decision of consolidative treatment following IC are not clear from the above studies. In general, outcomes are better in patients with a response to IC; however both Ho and Meijer report a 20% 5 year OS in patients with stable disease on IC \(^{66,67}\), indicating these patients can still obtain benefit. In general, the choice of consolidative treatment is best made on an individual basis with multidisciplinary input. Nonetheless, there are two situations which would sway our decision towards HDRT as opposed to surgery. The first is a patient with persistent N3 disease after IC, where the risk of relapse is high and HDRT represents a less invasive treatment option. The second is for a patient with cT4b disease who fails to obtain down staging with IC, where surgery is usually not feasible.

**The role of aggressive surgical / radiotherapeutic management in oligometastastic disease.**

- Routine practice of metastasectomy / localized treatment to metastatic disease in patients with oligometastatic or limited metastatic disease is not recommended. However, such treatment may be appropriate in selected cases. (See discussion).
- In metastatic UC of the bladder, the routine practice of RC or HDRT (+/- chemotherapy) to the primary is not recommended. However, such treatment may be appropriate in selected cases (See discussion).
- The decision to treat oligometastatic disease with local therapies should be made in a multidisciplinary context with involvement of an experienced medical oncologist, uro-oncologist and radiation oncologist where appropriate.

The targeting of oligometastatic disease with surgical resection and / or ablative radiotherapy has only been tested in small series of highly selected patients with no randomized studies to guide practice. While outcomes have been impressive with reports of 5 year OS of up to 65\% \(^{69,70}\), uncertainty exists as to whether favourable outcomes were the result of selection bias or from a therapeutic benefit of the localized therapy studied. Further compounding the problem of applying these studies to routine practice is the fact that the majority of studies were retrospective without clearly defined criteria for which patients should receive the localized treatment under consideration. The same limitation applies to the evidence for aggressive localized treatment of the pelvic primary with RC or HDRT (+/- concurrent chemotherapy) in a patient with metastatic disease. In short, the literature provides no level 1 evidence to be either prescriptive or proscriptive with regard to the above treatments. The existing literature is prone to methodological bias.\(^{71}\)

Individualization of local treatment following systemic treatment is the most judicious approach. The aggressiveness of the local treatment will vary according to the initial local stage and the subsequent local and systemic response to the chemotherapy. In any given patient, TURBT (trans-urethral resection of bladder tumor), pelvic radiotherapy with or without concurrent chemotherapy, metastasectomy or ablative radiotherapy may be appropriate. Recognizing this dearth of compelling data emphasizes that individually tailored treatment by a multidisciplinary team will serve the patient best.
Patients for whom multidisciplinary input may be useful include those with oligometastatic disease, advanced pelvic disease (without hematogenous metastases) with a response to systemic therapy, and those with hematogenous metastases with a complete response at least pertaining to their metastatic disease.

Future directions
The management of locally advanced and metastatic urothelial carcinoma is a rapidly changing field. Ongoing randomized phase III studies of immunotherapy for advanced urothelial carcinoma are summarized in Table 5. Additionally, work is being done on identifying predictive biomarkers which will help in patient selection. Upper tract urothelial carcinoma is associated with microsatellite instability in 3 – 6% of cases and this may be a useful biomarker to evaluate with respect to the efficacy of immunotherapy. The association with Lynch syndrome should be noted and the role of universal screening versus risk adapted screening could be evaluated in subsequent updates. Immunotherapy studies are also taking place in the earlier stages of disease which has the potential to alter the profile of the patient presenting with subsequent locally advanced or metastatic disease. Immunotherapy may also change the profile of patients being considered for aggressive local therapies in the context of metastatic disease. Due to the rapid evolution of therapy in this disease state, these consensus statements will need regular updating.
References


Figures and Tables

<table>
<thead>
<tr>
<th>Table 1. Recommended treatment schedules</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment regimen</td>
</tr>
<tr>
<td>-------------------</td>
</tr>
<tr>
<td>Gemcitabine, cisplatin (GC)</td>
</tr>
<tr>
<td>Dose dense-Methotrexate, vinblastine, doxorubicin, cisplatin (DD-MVAC)</td>
</tr>
<tr>
<td>Gemcitabine, Carboplatin (GCa)</td>
</tr>
<tr>
<td>Gemcitabine (G)</td>
</tr>
<tr>
<td>Paclitaxel (P)</td>
</tr>
<tr>
<td>Docetaxel (D)</td>
</tr>
<tr>
<td>Pembrolizumab</td>
</tr>
</tbody>
</table>
Table 2. Summary of first-line immunotherapy studies in cisplatin ineligible patients with advanced urothelial carcinoma

<table>
<thead>
<tr>
<th></th>
<th>Pembrolizumab: Keynote 052</th>
<th>Atezolizumab: Invigor 210 cohort 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study type</td>
<td>Multicentre, single-arm phase 2 Cisplatin-ineligible, first-line</td>
<td>Multicentre, single-arm, phase 2 Cisplatin-ineligible, first-line</td>
</tr>
<tr>
<td>Treatment regimen</td>
<td>Pembrolizumab 200 mg IV 3 weekly</td>
<td>Atezolizumab 1200 mg IV 3 weekly</td>
</tr>
<tr>
<td>Number of patients</td>
<td>370</td>
<td>119</td>
</tr>
<tr>
<td>Median followup (months)</td>
<td>11.5</td>
<td>17.2</td>
</tr>
<tr>
<td>ECOG 2%</td>
<td>42</td>
<td>27</td>
</tr>
<tr>
<td>Visceral metastases%</td>
<td>85</td>
<td>66</td>
</tr>
<tr>
<td>ORR%</td>
<td>29</td>
<td>23</td>
</tr>
<tr>
<td>Cr%</td>
<td>8</td>
<td>9</td>
</tr>
<tr>
<td>Response duration</td>
<td>68% ongoing at 12 months</td>
<td>70% ongoing at time of assessment</td>
</tr>
<tr>
<td>Median OS (months)</td>
<td>11.5</td>
<td>15.9</td>
</tr>
<tr>
<td>Effect of PD-L1 positivity</td>
<td>Combined positive score (CPS):</td>
<td>IC 2/3: ORR 28% IC 1: ORR 21% IC 0: ORR 21%</td>
</tr>
<tr>
<td></td>
<td>≥10%: ORR 47.3%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1–10%: ORR: 20%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;1%: ORR 5%</td>
<td></td>
</tr>
<tr>
<td>Grade ¾ toxicity</td>
<td>16%</td>
<td>16%</td>
</tr>
<tr>
<td>Reference</td>
<td>Balar 2017\textsuperscript{26} Vuky\textsuperscript{27}</td>
<td>Balar\textsuperscript{28}</td>
</tr>
</tbody>
</table>

Cr: creatinine; ECOG: Eastern Cooperative Oncology Group; ORR: overall response rate; OS: overall survival.
CUAJ – Consensus Statement
Warren et al
Unresectable locally advanced and metastatic urothelial carcinoma

Table 3. Phase 1/2 studies of checkpoint inhibitors following platinum-based treatment

<table>
<thead>
<tr>
<th>Checkpoint inhibitor</th>
<th>Nivolumab Checkmate 032</th>
<th>Nivolumab Checkmate 275</th>
<th>Durvalumab MEDI4736</th>
<th>Atezolizumab Invigor 210 cohort II</th>
<th>Atezolizumab Javelin Solid Tumour</th>
<th>Pembrolizumab Keynote 012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study type</td>
<td>Phase 1/2</td>
<td>Phase 2</td>
<td>Ph 1/2</td>
<td>Phase 2</td>
<td>Phase 1</td>
<td>Phase 1b</td>
</tr>
<tr>
<td>Patients</td>
<td>86</td>
<td>270</td>
<td>191</td>
<td>315</td>
<td>95</td>
<td>161</td>
</tr>
<tr>
<td>ORR% (95% CI)</td>
<td>24 (15 –35)</td>
<td>20 (15–24)</td>
<td>18 (13–24)</td>
<td>15 (11–19)</td>
<td>26 (18–36)</td>
<td>17 (11–24)</td>
</tr>
<tr>
<td>Cr%</td>
<td>6</td>
<td>2</td>
<td>4</td>
<td>5</td>
<td>9</td>
<td>6</td>
</tr>
<tr>
<td>Response duration</td>
<td>Median 9.4 months</td>
<td>77% ongoing at 6 months</td>
<td>50% ongoing at 6m</td>
<td>84% ongoing at median f/u 11.7m</td>
<td>Median 22.1m</td>
<td>Median NR (not reached)</td>
</tr>
<tr>
<td>mPFS months</td>
<td>2.8</td>
<td>2</td>
<td>1.4</td>
<td>2.1</td>
<td>2.7</td>
<td>1.6</td>
</tr>
<tr>
<td>mOS months</td>
<td>9.7</td>
<td>8.7</td>
<td>18</td>
<td>7.9</td>
<td>10.1</td>
<td>6.5</td>
</tr>
<tr>
<td>Grade 3–5 toxicity%</td>
<td>22</td>
<td>18</td>
<td>6.8</td>
<td>16</td>
<td>9%</td>
<td>8</td>
</tr>
<tr>
<td>Effect of PD-L1 on ORR%</td>
<td>≥1%: 24%</td>
<td>≥1%: 24%</td>
<td>≥25% IC/TC: 28%</td>
<td>IC2/3: 27%</td>
<td>IC 2/3: 40%</td>
<td>≥5%: 24%</td>
</tr>
<tr>
<td></td>
<td>&lt;1%: 26%</td>
<td>&lt;1%: 16%</td>
<td>&lt;25% IC/TC: 5%</td>
<td>ITT: 15%</td>
<td>IC 0/1: 11%</td>
<td>&lt;5%: 14%</td>
</tr>
<tr>
<td></td>
<td>≥1%: 24%</td>
<td>≥1%: 24%</td>
<td>&gt;25% IC/TC: 28%</td>
<td>IC2/3: 27%</td>
<td>IC 2/3: 40%</td>
<td>≥5%: 24%</td>
</tr>
<tr>
<td></td>
<td>&lt;1%: 16%</td>
<td>&lt;1%: 16%</td>
<td>&lt;25% IC/TC: 5%</td>
<td>ITT: 15%</td>
<td>IC 0/1: 11%</td>
<td>&lt;5%: 14%</td>
</tr>
<tr>
<td></td>
<td>≥5%: 24%</td>
<td>≥5%: 24%</td>
<td>&gt;25% IC/TC: 28%</td>
<td>IC2/3: 27%</td>
<td>IC 2/3: 40%</td>
<td>≥5%: 24%</td>
</tr>
<tr>
<td></td>
<td>&lt;5%: 14%</td>
<td>&lt;5%: 14%</td>
<td>&lt;25% IC/TC: 5%</td>
<td>ITT: 15%</td>
<td>IC 0/1: 11%</td>
<td>&lt;5%: 14%</td>
</tr>
<tr>
<td></td>
<td>≥1%: 24%</td>
<td>≥1%: 24%</td>
<td>&gt;25% IC/TC: 28%</td>
<td>IC2/3: 27%</td>
<td>IC 2/3: 40%</td>
<td>≥5%: 24%</td>
</tr>
<tr>
<td></td>
<td>&lt;1%: 0% (combined TC/IC measured)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Reference

Sharma 2016\(^{40}\)  Sharma 2017\(^{41}\)  Massard 2016\(^{42}\); Powles 2018\(^{43}\)  Rosenberg 2016\(^{44}\)  Petrylak 2018\(^{45}\)  Patel 2016\(^{46}\)  Plimack 2017\(^{47}\)

C: confidence interval; IC: immune cells; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; TC: tumour cells;
Table 4. Studies of cT4b and/or cN1-3 urothelial carcinoma treated with induction chemotherapy (IC) followed by consolidation with surgery or HDRT

<table>
<thead>
<tr>
<th>Study</th>
<th>Clinical stage</th>
<th>Patients (n)</th>
<th>Induction chemotherapy</th>
<th>Consolidative treatment</th>
<th>Selection criteria for RC and/or HDRT</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zargar-Shostari $^{58}$</td>
<td>T1 – 4a N1-3</td>
<td>304</td>
<td>GC 43% MVAC 42% Other 15%</td>
<td>RC/PLND</td>
<td>Not defined</td>
<td>Median OS 23m 50% died in followup</td>
</tr>
<tr>
<td>Herr $^{65}$</td>
<td>T4bNx or T3-4N2-3</td>
<td>80 (selected from 207)</td>
<td>MVAC 75% Other 25%</td>
<td>RC +/- PLND</td>
<td>Not defined</td>
<td>42% survived 9 months to 5 years MVAC treated pts: 32% OS at 5 years 5-year CSS (cancer specific survival) 23%</td>
</tr>
<tr>
<td>Nieuwenjuijzen $^{60}$</td>
<td>Biopsy proven N+ disease (40% FNA, 60% PLND)</td>
<td>40 (selected from 52)</td>
<td>MVAC / dd-MVAC</td>
<td>RC/PLND</td>
<td>Response to induction chemotherapy</td>
<td>5-year CSS (cancer specific survival) 23%</td>
</tr>
<tr>
<td>Ho $^{66}$</td>
<td>cN1-3: 53% cM1: retroperitoneal nodes 47%</td>
<td>55</td>
<td>Cisplatin based 93%</td>
<td>RC, PLND +/- RPLND</td>
<td>Not defined</td>
<td>5-year CSS: 40%</td>
</tr>
<tr>
<td>Black $^{61}$</td>
<td>Tb4</td>
<td>23</td>
<td>Preoperative chemotherapy in 83%</td>
<td>RC, PLND</td>
<td>Not defined, but generally major response to IC required</td>
<td>5-year OS: 60%</td>
</tr>
</tbody>
</table>
### Consensus Statement

**Unresectable locally advanced and metastatic urothelial carcinoma**

<table>
<thead>
<tr>
<th>Study</th>
<th>Stage</th>
<th>Therapy</th>
<th>CR</th>
<th>PR</th>
<th>OS</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Als(^62)</td>
<td>cTb4 or cN2-3</td>
<td>GC</td>
<td>CR: observation PR: RC/PLND or HDRT</td>
<td></td>
<td></td>
<td>Clinical CR: close observation Clinical PR: investigators choice of RC or RT</td>
</tr>
<tr>
<td>Urakami(^63)</td>
<td>cN1-3 and M1a lymph nodes only (30%)</td>
<td>Platinum based (GC based in 57%).</td>
<td></td>
<td></td>
<td></td>
<td>Stable disease or response</td>
</tr>
<tr>
<td></td>
<td>84 (25 observed after clinical CR, 7 RC 9 HDRT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5-year OS: Overall 21% CR with observation 42% NED from surgery or XRT: 49%</td>
</tr>
<tr>
<td></td>
<td>51 (selected from 60: 29 upper tract, 31 bladder)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5-year OS (including non-operated candidates) 42%</td>
</tr>
<tr>
<td>Ghadjar(^64)</td>
<td>T4, N1 – 3, M1 regional nodes</td>
<td>GC/GCa</td>
<td>RC/PLND</td>
<td></td>
<td></td>
<td>5-year OS 46%</td>
</tr>
<tr>
<td>Meijer(^6/)</td>
<td>cN1-3 M1a: retroperitoneal nodes</td>
<td>MVAC / dd-MVAC 62% CG / CarbG 38%</td>
<td>RC/PLND</td>
<td></td>
<td></td>
<td>Overall 5-year OS of 29%</td>
</tr>
<tr>
<td></td>
<td>149 (118 RC/PLND 14 HDRT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 5. Current phase 3 studies of immunotherapy in locally advanced and metastatic urothelial carcinoma

<table>
<thead>
<tr>
<th>Study</th>
<th>ClinicalTrials.gov Identifier</th>
<th>Disease state</th>
<th>Treatment arms</th>
<th>Estimated completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imvigor 130</td>
<td>NCT02807636</td>
<td>1st line</td>
<td>Atezolizumab vs. Atezolizumab/platinum based chemotherapy vs. platinum based chemotherapy</td>
<td>November 2020</td>
</tr>
<tr>
<td>Keynote 361</td>
<td>NCT02853305</td>
<td>1st line</td>
<td>Pembrolizumab vs. Pembrolizumab/platinum based chemotherapy vs. platinum based chemotherapy</td>
<td>May 2020</td>
</tr>
<tr>
<td>Danube</td>
<td>NCT02516241</td>
<td>1st line</td>
<td>Durvalumab + tremelimumab vs durvalumab vs. standard chemotherapy</td>
<td>September 2019</td>
</tr>
<tr>
<td>Javelin Bladder 100</td>
<td>NCT02603432</td>
<td>Maintenance following 1st line</td>
<td>Avelumab + BSC vs. BSC alone</td>
<td>July 2020</td>
</tr>
<tr>
<td>Checkmate 901</td>
<td>NCT03036098</td>
<td>1st line</td>
<td>Nivolumab/ipilimumab vs. platinum-based chemotherapy Nivolumab/cisplatin gemcitabine vs. cisplatin gemcitabine alone</td>
<td>December 2022</td>
</tr>
</tbody>
</table>